Drugs / GFB-887
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03970122 | May 2019 → Mar 2020 | — | Goldfinch Bio, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04950114 | Jul 2021 → Nov 2022 | focal segmental glomerulosclerosis, glomerulonephritis, nephrosis | Goldfinch Bio, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04387448 | Jul 2020 → Nov 2022 | diabetes mellitus, diabetic kidney disease, focal segmental glomerulosclerosis, minimal change disease +1 | Goldfinch Bio, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFB-887 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04950114 ↗ |
| Action | Inhibit | “GFB-887, a TRPC5 Channel Inhibitor” NCT03970122 ↗ |
| Modality | Small molecule | “GFB-887 is a potent, small molecule inhibitor of TRPC5.” NCT04950114 ↗ |
| Target | TRPC5 | “GFB-887, a TRPC5 Channel Inhibitor” NCT03970122 ↗ |